T. Rowe Price Health Sciences Portfolio is a registered fund series of T. ROWE PRICE EQUITY SERIES, INC. (series S000002083). Net assets $662.6M as of 2026-03-31.
Showing 15 of 200 holdings by value.
| Holding | Ticker | Value | % of fund |
|---|---|---|---|
| ELI LILLY & CO | — | $67.7M | 1021.50% |
| THERMO FISHER SCIENTIFIC INC | — | $27.0M | 407.55% |
| INTUITIVE SURGICAL INC | — | $24.4M | 368.28% |
| STRYKER CORP | — | $23.1M | 348.87% |
| MERCK & CO. INC. | — | $22.9M | 345.73% |
| ASTRAZENECA PLC | — | $21.0M | 317.61% |
| UNITEDHEALTH GROUP INC | — | $20.5M | 310.05% |
| ARGENX SE - ADR | — | $19.4M | 292.65% |
| ABBVIE INC | — | $19.1M | 288.01% |
| REGENERON PHARMACEUTICALS | — | $17.8M | 268.20% |
| GILEAD SCIENCES INC | — | $17.3M | 260.99% |
| JOHNSON & JOHNSON | — | $16.3M | 245.69% |
| VERTEX PHARMACEUTICALS INC | — | $16.1M | 242.91% |
| DANAHER CORP | — | $13.6M | 205.08% |
| ALNYLAM PHARMACEUTICALS INC | — | $10.8M | 162.93% |
| Report date | Net assets |
|---|---|
| 2026-03-31 | $662.6M |
| 2025-12-31 | $729.8M |
| 2025-09-30 | $644.4M |
| 2025-06-30 | $631.0M |
| 2025-03-31 | $660.1M |
| 2024-12-31 | $665.6M |
| 2024-09-30 | $755.6M |
| 2024-06-30 | $719.0M |